Skip to main content
Midas Edge

Sagimet Biosciences Inc.

For the period ended Jun 30, 2025. Filed Aug 13, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 13, 2025

SGMT$10.89+0.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Statements of Stockholders’ Equity (unaudited)

CONDENSED STATEMENTS OF

STOCKHOLDERS’ EQUITY

(in thousands, except share amounts)

​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​
​ · ​ · Series A · ​ · ​ · Series B · ​ · Additional · ​ · ​ · ​ · ​ · Other · ​ · Total
​ · ​ · Common Stock · Common Stock · ​ · Paid-in · ​ · Accumulated · ​ · Comprehensive · ​ · Stockholders’
​ · Shares · Amount · Shares · Amount · Capital · Deficit · Income (Loss) · Equity
Balance at January 1, 2025​​30,674,855​$3​​1,520,490​$—​$450,883​$(295,311)​$230​$155,805
Stock-based compensation expense​—​—​​—​—​1,472​—​—​1,472
Unrealized loss on marketable securities​—​—​​—​—​—​—​(109)​(109)
Net loss​—​—​​—​—​—​​(18,176)​—​(18,176)
Balance at March 31, 2025​30,674,855​$3​​1,520,490​$—​$452,355​$(313,487)​$121​$138,992
Issuance of Series A common stock upon exercise of stock options​​99​—​​—​—​1​—​—​1
Stock-based compensation expense​—​—​​—​—​1,598​—​—​1,598
Unrealized loss on marketable securities​—​—​​—​—​—​—​(45)​(45)
Net loss​—​—​​—​—​—​(10,386)​—​(10,386)
Balance at June 30, 2025​30,674,954​$3​​1,520,490​$—​$453,954​$(323,873)​$76​$130,160
​​​​​​​​​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​
​ · ​ · Series A · ​ · ​ · Series B · ​ · Additional · ​ · ​ · ​ · ​ · Other · ​ · Total
​ · ​ · Common Stock · Common Stock · ​ · Paid-in · ​ · Accumulated · ​ · Comprehensive · ​ · Stockholders’
​ · ​ · Shares · Amount · Shares · Amount · Capital · Deficit · Income (Loss) · Equity
Balance at January 1, 2024​​21,375,402​$2​​1,520,490​$—​$340,777​$(249,744)​$30​$91,065
Sale of Series A common stock, net of issuance costs of $7,796​​9,000,000​​1​​​—​​—​​104,731​​—​​—​​104,732
Issuance of Series A common stock upon exercise of stock options​​17,995​​—​​​—​​—​​114​​—​​—​​114
Stock-based compensation expense​—​—​​—​—​759​—​—​759
Unrealized loss on marketable securities​—​—​​—​—​—​—​(23)​(23)
Net loss​—​—​​—​—​—​(6,629)​—​​(6,629)
Balance at March 31, 2024​30,393,397​$3​​1,520,490​$—​$446,381​$(256,373)​$7​$190,018
Issuance costs related to sale of Series A common stock​—​​—​​​—​​—​(27)​—​—​(27)
Stock-based compensation expense​​—​​—​​​—​​—​​1,449​​—​​—​​1,449
Unrealized loss on marketable securities​—​​—​​​—​​—​—​—​(30)​(30)
Net loss​—​​—​​​—​​—​—​(8,118)​—​​(8,118)
Balance at June 30, 2024​30,393,397​$3​​​1,520,490​$—​$447,803​$(264,491)​$(23)​$183,292

The accompanying notes are an integral part of these unaudited condensed financial statements

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.